← All trials
NCT00375388
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 1998
- Primary completion
- —
- Completion date
- Oct 1, 2002
- First posted
- —
- Last posted
- —
- Enrollment
- 400
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- Bethesda General Hospital, HoogeveenLead sponsor
- LifeScanCollaborator
- DuPont MerckCollaborator
- TakedaCollaborator
- Merck KGaACollaborator
- MerckCollaborator
- Novo NordiskCollaborator
- Bethesda Diabetes Center, HoogeveenOverall official - principal investigator
- Maastricht UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.